Day: April 15, 2025

April 15, 2025Announcement no. 11                                                                          Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced yesterday in company announcement 10. Peter Mørch Eriksen, CEO of BioPorto, says: “I am delighted by the strong commitments from both our largest existing shareholders and new investors drawn to our company and the investment case. The continuous support of our owners and...

April 15, 2025Announcement no. 11                                                                          Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced earlier today in company announcement 10. Peter Mørch Eriksen, CEO of BioPorto, says: “I am delighted by the strong commitments from both our largest existing shareholders and new investors drawn to our company and the investment case. The continuous support of our owners...

Company Announcement No. 1153 As of today, all closing conditions for DSV A/S’ pending acquisition of the global freight forwarding and contract logistics business DB Schenker operated by Schenker AG and its affiliates (“Schenker”) from Deutsche Bahn AG have been fulfilled, including approval by the European Commission and the expiration of the applicable waiting period in the US. Please refer to announcement no. 1132 of 13 September 2024. The parties are now able to complete the transaction, which is expected to take place on 30 April 2025. Due to the expected completion of the Schenker acquisition, the interim results for the first quarter of 2025 for DSV A/S, which is scheduled for 29 April 2025, will be postponed to 30 April 2025, where further details and preliminary financial information related to the acquisition of Schenker will...

Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules SIKA IS GENERATING GROWTH IN Q1 DESPITE UNPREDICTABLE MARKETS AND CONTINUES INVESTING WORLDWIDEGrowth in local currencies of +1.9% (growth in CHF: +1.1%) Q1 sales of CHF 2,678.3 million (previous year: CHF 2,648.0 million) Organic growth of 0.9% Acquisition effect of 1.0% Targeted investment in future growthAcquisition of Elmich (Singapore), Cromar (UK), and HPS (USA) Opening of new factories in Singapore, Xi’an (China), Quito (Ecuador), and Ust-Kamenogorsk (Kazakhstan)Outlook for fiscal 2025:Sika confirms the outlook, but points to increased market uncertainties arising from potentially prolonged trade conflicts   Expected sales increase in local currencies of 3-6% Over-proportional increase in EBITDA and EBITDA margin of between 19.5%-19.8%Confirmation...

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of...

CALGARY, Alberta, April 14, 2025 (GLOBE NEWSWIRE) — PrairieSky Royalty Ltd. (“PrairieSky” or the “Company“) (TSX: PSK) is pleased to announce that its shareholders approved all resolutions at the annual general meeting of shareholders of the Company held on April 14, 2025 (the “Meeting“) in Calgary, Alberta. The resolutions approved at the Meeting were as follows: The resolution to appoint the seven (7) nominees as directors of the Company to serve until the next annual meeting of shareholders of the Company, or until their successors are elected or appointed, was passed by way of ballot and each of the directors received the following votes for their election:Margaret A. McKenzie 212,802,872 (99.914%)Anna M. Alderson 212,841,516 (99.932%)Anuroop S. Duggal 209,670,592 (98.443%)P....